Jefferies Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $45
Immunocore Holdings Cut to Equal-Weight From Overweight by Morgan Stanley
Immunocore Hldgs Analyst Ratings
Morgan Stanley Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $35
Goldman Sachs Maintains Immunocore(IMCR.US) With Buy Rating, Announces Target Price $74
Immunocore Hldgs Analyst Ratings
Mizuho Securities Downgrades Immunocore(IMCR.US) to Hold Rating, Cuts Target Price to $38
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $74
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
Oppenheimer Trims Immunocore Price Target to $88 From $89, Maintains Outperform Rating
Barclays Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $66
Barclays Keeps Their Buy Rating on Immunocore Holdings (IMCR)
Needham Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $71
TD Cowen Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $60
Immunocore Holdings: Strong Market Performance and Promising Pipeline Drive Buy Rating
UBS Initiates Coverage On Immunocore Hldgs With Sell Rating, Announces Price Target of $24
H.C. Wainwright Maintains Immunocore(IMCR.US) With Buy Rating, Maintains Target Price $100
Immunocore Holdings Is Maintained at Overweight by Morgan Stanley
Morgan Stanley Maintains Immunocore(IMCR.US) With Buy Rating, Cuts Target Price to $74
Immunocore Hldgs Analyst Ratings